Geumji Seung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Geumji Seung has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hyobi Kim
Viral Disease Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Republic of Korea
1 shared publication - Il Jang
Veterinary Drugs and Biologics Division, Animal and Plant Quarantine Agency, 177, Hyeoksin 8-ro, Gimcheon-si, Korea
1 shared publication - Ji-Ye Kim
Avian disease division, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-si, Republic of Korea
1 shared publication - Ji-Yeon Kim
Veterinary Drugs and Biologics Division, Animal and Plant Quaratine Agency (APQA), Gimcheon-Si, Republic of Korea
1 shared publication - Keun-Woo Lee
College of Veterinary Medicine and Zoonoses Research Institute, Kyungpook National University, Daegu 41566, Korea
1 shared publication - Moon Her
Avian disease division, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon-si, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 31 December 2022
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 62 (4) , e29
Serological responses and protection levels in chickens administered with Newcastle disease vaccines
Vaccination against Newcastle disease (ND) is the most effective means of controlling the disease, and these vaccines are commercialized only after their safety and effectiveness have been verified through tests that comply with Korean Standards of National Lot Release for Veterinary Biologics. This study investigated whether a relatively convenient and safe serological test can be used in place of the challenge test using highly virulent ND virus. Hemagglutination inhibition (HI) assay and enzyme-linked immunosorbent assay (ELISA) were considered positive of log2 2 or more and cutoff value of 200 or more, respectively, in both live and inactivated vaccines. However, when the antibody levels of the live and inactivated vaccines induced using the Ulster 2C, KBNP-C4152R2L, and K148/08 strains were compared, the antibody titers for inactivated vaccines were significantly higher than those for live vaccines in both the HI assay and ELISA. A strong positive correlation was observed between HI and ELISA antibody titers. The live vaccines corresponded to a survival rates of ≥ 80% and the inactivated vaccines corresponded to 100% survival rates. This study confirmed that standard efficacy tests can serve as serological tests, and can replace the challenge test and that the vaccine approval process can be improved.
- 31 December 2022
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 62 (4) , e29
Open AccessSerological responses and protection levels in chickens administered with Newcastle disease vaccines
Vaccination against Newcastle disease (ND) is the most effective means of controlling the disease, and these vaccines are commercialized only after their safety and effectiveness have been verified through tests that comply with Korean Standards of National Lot Release for Veterinary Biologics. This study investigated whether a relatively convenient and safe serological test can be used in place of the challenge test using highly virulent ND virus. Hemagglutination inhibition (HI) assay and enzyme-linked immunosorbent assay (ELISA) were considered positive of log2 2 or more and cutoff value of 200 or more, respectively, in both live and inactivated vaccines. However, when the antibody levels of the live and inactivated vaccines induced using the Ulster 2C, KBNP-C4152R2L, and K148/08 strains were compared, the antibody titers for inactivated vaccines were significantly higher than those for live vaccines in both the HI assay and ELISA. A strong positive correlation was observed between HI and ELISA antibody titers. The live vaccines corresponded to a survival rates of ≥ 80% and the inactivated vaccines corresponded to 100% survival rates. This study confirmed that standard efficacy tests can serve as serological tests, and can replace the challenge test and that the vaccine approval process can be improved.